Press Releases Ypsomed Group

Burgdorf - On 27 June 2018, the Annual General Meeting of the Ypsomed Group elected Paul Fonteyne as a new member of the Board of Directors and the Compensation Committee of the Ypsomed Group. He is Chairman of Boerhinger Ingelheim USA, and until March 2018 he was President and CEO of Boehringer Ingelheim USA. Paul Fonteyne follows Prof. em. Dr. Norbert Thom, who resigned at the 2018 Annual General Meeting.

Ypsomed expands to North America

Press Releases Ypsomed Group

Burgdorf – Ypsomed establishes its first subsidiary in North America, Canada. The foundation in Canada is another important milestone in the consistently pursued growth strategy. At the same time, the mylife™ YpsoPump® insulin pump is launched in India.

Swisscom and Ypsomed test 5G in production operations for the first time

Press Releases Ypsomed Group

Burgdorf - Swisscom and Ypsomed have been cooperating since the spring of 2017 to develop application options for the latest generation of mobile communications. Ypsomed has digitised selected production processes with 5G. This simplifies processes considerably, makes them even safer and more efficient.

Ypsomed is driving the digitisation of its portfolio

Press Releases Ypsomed Group

Burgdorf – Ypsomed continues to expand its offers for digital diabetes therapy with the launch of the mylife™ App. The mylife™ App is connected to the mylife™ YpsoPump® insulin pump via Bluetooth® and continuously records current therapy data. Digital therapy solutions add to customer benefit and increase the success of therapy long-term.

Press Releases Ypsomed Group

Burgdorf – Ypsomed and the US Bigfoot Biomedical company today announced their agreement for a partnership. Ypsomed will supply Bigfoot Biomedical with a modified, patented version of the Orbit infusion set. This will be used by Bigfoot in their clinical study on automated insulin therapy in people with diabetes.